Buyback Spend for Regeneron Pharmaceuticals (REGN)
Buyback Spend for Regeneron Pharmaceuticals (REGN): headline value $3.44B · YoY -5.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingBuyback SpendSwitch metric
Latest period
$3.44B
YoY change
-5.3%
5Y CAGR
-12.0%
Peak year (2020)
$6.53B
Latest annual
$3.44B
Buyback Spend history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Buyback Spend history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
| Fiscal year | Period ended | Reported | Buyback Spend | YoY |
|---|---|---|---|---|
| 2025 | $3.44B | -5.3% | ||
| 2024 | $3.63B | +23.7% | ||
| 2023 | $2.94B | +16.1% | ||
| 2022 | $2.53B | -5.6% | ||
| 2021 | $2.68B | -59.0% | ||
| 2020 | $6.53B | +1307.1% | ||
| 2019 | $463.90M | +142.1% | ||
| 2018 | $191.60M | -36.5% | ||
| 2017 | $301.70M | +110.7% | ||
| 2016 | $143.20M | -10.8% | ||
| 2015 | $160.54M | -40.0% | ||
| 2014 | $267.58M | +37.2% | ||
| 2013 | $195.09M | +19.5% | ||
| 2012 | $163.30M | +551.2% | ||
| 2011 | $25.08M | +560.3% | ||
| 2010 | $3.80M | — | ||
| 2009 | $0 | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | -100.0% | ||
| 2004 | $888,000 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — |
Buyback Spend values are taken from Regeneron Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Regeneron Pharmaceuticals (REGN) buyback spend totalled $3.44B – declined 5.3% year-over-year.
Through 2020–2025 (5 years), Regeneron Pharmaceuticals buyback spend delivered a -12.0% annualised rate; with a net decline across the window.
Regeneron Pharmaceuticals buyback spend plunged from $6.53B in 2020 to $3.44B in 2025, a 47.3% drawdown.
The dataset's maximum buyback spend sits at $6.53B (2020); the minimum reading of $0 dates to 1991.
Among 8 Healthcare peers, Regeneron Pharmaceuticals (REGN) ranks 5th; the peer median for buyback spend is $2.75B.
Regeneron Pharmaceuticals Buyback Spend by Year
Regeneron Pharmaceuticals Buyback Spend 2025: $3.44B
Regeneron Pharmaceuticals buyback spend in 2025 was $3.44B, declined 5.3% below 2024.
Regeneron Pharmaceuticals Buyback Spend 2024: $3.63B
Regeneron Pharmaceuticals buyback spend in 2024 was $3.63B, grew 23.7% from 2023.
Regeneron Pharmaceuticals Buyback Spend 2023: $2.94B
Regeneron Pharmaceuticals buyback spend in 2023 was $2.94B, grew 16.1% from 2022.
Regeneron Pharmaceuticals Buyback Spend 2022: $2.53B
Regeneron Pharmaceuticals buyback spend in 2022 was $2.53B, declined 5.6% below 2021.
Regeneron Pharmaceuticals Buyback Spend 2021: $2.68B
Regeneron Pharmaceuticals buyback spend in 2021 was $2.68B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Buyback Spend
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $5.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $5.08B | Healthcare |
| Eli Lilly and Company (LLY) | $4.11B | Healthcare |
| Novo Nordisk A/S (NVO) | $1.39B | Healthcare |
| AbbVie Inc. (ABBV) | $980.00M | Healthcare |
| AstraZeneca PLC (AZN) | $719.66M | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's buyback spend?
Latest reported buyback spend for Regeneron Pharmaceuticals (REGN) is $3.44B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals buyback spend changed year-over-year?
Regeneron Pharmaceuticals (REGN) buyback spend changed -5.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals buyback spend?
Regeneron Pharmaceuticals (REGN) buyback spend compound annual growth rate is -12.0% over the most recent 5 years available.
When did Regeneron Pharmaceuticals buyback spend hit its highest annual value?
Regeneron Pharmaceuticals buyback spend reached its highest annual value of $6.53B in 2020.
What was Regeneron Pharmaceuticals buyback spend in 2024?
Regeneron Pharmaceuticals (REGN) buyback spend in 2024 was $3.63B.
What was Regeneron Pharmaceuticals buyback spend in 2025?
Regeneron Pharmaceuticals (REGN) buyback spend in 2025 was $3.44B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.